Post by mango on Jun 3, 2017 10:00:00 GMT -5
New MannKind International Patent Application Published 6/1/2017. This is a continuation
Application Number: 15356292
Application Date: 18.11.2016
Publication Number: 20170152206
Publication Date: 01.06.2017
Applicants: MannKind Corporation
Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
Title: (EN) IRE-1alpha INHIBITORS
Abstract: (EN)
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
patentscope.wipo.int/search/en/detail.jsf?docId=US197905793&recNum=1&office=&queryString=ALL%3A%28MannKind%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=1470
Application Number: 15356292
Application Date: 18.11.2016
Publication Number: 20170152206
Publication Date: 01.06.2017
Applicants: MannKind Corporation
Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
Title: (EN) IRE-1alpha INHIBITORS
Abstract: (EN)
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
patentscope.wipo.int/search/en/detail.jsf?docId=US197905793&recNum=1&office=&queryString=ALL%3A%28MannKind%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=1470